Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1

通过靶向补体受体C5aR1改善免疫抑制微环境中的放射治疗

阅读:5
作者:Callum Beach ,David MacLean ,Dominika Majorova ,Stavros Melemenidis ,Dhanya K Nambiar ,Ryan K Kim ,Gabriel N Valbuena ,Silvia Guglietta ,Carsten Krieg ,Mahnaz Darvish-Damavandi ,Tatsuya Suwa ,Alistair Easton ,Lily Vs Hillson ,Ashley K McCulloch ,Ross K McMahon ,Kathryn Pennel ,Joanne Edwards ,Sean M O'Cathail ,Campbell S Roxburgh ,Enric Domingo ,Eui Jung Moon ,Dadi Jiang ,Yanyan Jiang ,Qingyang Zhang ,Albert C Koong ,Trent M Woodruff ,Edward E Graves ,Tim Maughan ,Simon Ja Buczacki ,Manuel Stucki ,Quynh-Thu Le ,Simon J Leedham ,Amato J Giaccia ,Monica M Olcina

Abstract

An immunosuppressive microenvironment causes poor tumor T cell infiltration and is associated with reduced patient overall survival in colorectal cancer. How to improve treatment responses in these tumors is still a challenge. Using an integrated screening approach to identify cancer-specific vulnerabilities, we identified complement receptor C5aR1 as a druggable target, which when inhibited improved radiotherapy, even in tumors displaying immunosuppressive features and poor CD8+ T cell infiltration. While C5aR1 is well-known for its role in the immune compartment, we found that C5aR1 is also robustly expressed on malignant epithelial cells, highlighting potential tumor cell-specific functions. C5aR1 targeting resulted in increased NF-κB-dependent apoptosis specifically in tumors and not normal tissues, indicating that, in malignant cells, C5aR1 primarily regulated cell fate. Collectively, these data revealed that increased complement gene expression is part of the stress response mounted by irradiated tumors and that targeting C5aR1 could improve radiotherapy, even in tumors displaying immunosuppressive features.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。